STOK

Latest SEC Filings & News for STOK

1 most recent filing and news item mentioning STOK. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/STOK/news?limit=20"

Pull STOK filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OtherJun 30, 2026Positive

Stoke completes Zorevunersen Phase 3 enrollment

Stoke Therapeutics reported completing enrollment for the zorevunersen Phase 3 EMPEROR study involving 162 patients. The biotech firm plans a U.S. NDA submission in early 2027 and targets a potential launch by 2028.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.